DNA Methylation Alteration

DNA Methylation Alteration is a change in the pattern or overall level of 5-methylcytosine marks deposited on cytosine bases within CpG dinucleotides across the genome, disrupting the normal balance between silenced and active chromatin regions and thereby driving inappropriate activation or repression of genes central to cell cycle control, DNA repair, differentiation, and genome stability.

Normal DNA Methylation Landscape

Establishment and Maintenance

DNA methylation is deposited by DNA methyltransferase enzymes, with de novo methyltransferases establishing new methylation patterns during development and a maintenance methyltransferase copying existing patterns onto newly synthesized DNA strands after replication, ensuring that methylation marks are faithfully inherited through successive cell divisions.

Functional Distribution Across the Genome

In normal cells, the bulk of the genome, including repetitive elements and intergenic regions, carries dense methylation that maintains chromatin in a compact, transcriptionally silent state, while CpG islands located at gene promoters generally remain unmethylated, permitting transcription factor access and active gene expression. This distribution stabilizes genome architecture while preserving the flexibility of gene regulation.

Categories of Alteration in Cancer

Global Hypomethylation

Cancer genomes frequently show a genome-wide reduction in methylation, most pronounced in repetitive sequences, transposable elements, and intergenic regions. This loss destabilizes heterochromatin, permits reactivation of transposable elements that can insert into new genomic locations, and contributes to chromosomal instability by weakening the structural integrity of pericentromeric regions.

Focal Promoter Hypermethylation

In contrast to global loss, specific CpG islands at the promoters of tumor suppressor genes become densely and abnormally hypermethylated. This focal gain recruits methyl-binding domain proteins and associated repressive complexes that compact local chromatin, silencing genes responsible for cell cycle checkpoint control, apoptosis induction, and DNA mismatch repair.

Imprinting and Allele-Specific Disruption

Some methylation alterations disrupt genomic imprinting, the parent-of-origin-specific methylation pattern that normally silences one allele of certain genes. Loss of imprinting can reactivate a normally silent allele of a growth-promoting gene, effectively doubling its expression and providing a proliferative advantage.

Mechanistic Drivers

Mutations in Methylation Machinery

Recurrent mutations affecting de novo methyltransferases and enzymes that catalyze active demethylation directly reshape the methylome, producing distinctive genome-wide methylation signatures that are characteristic of specific cancer subtypes.

Metabolic Influence on Methylation

Because methylation reactions depend on the universal methyl donor produced through one-carbon metabolism, and demethylation reactions depend on metabolites such as alpha-ketoglutarate, disruptions in cellular metabolism, including mutations that generate competitive inhibitors of demethylating enzymes, can globally shift the balance between methylation and demethylation independent of any direct mutation in the methylation machinery itself.

Downstream Consequences

Gene Silencing of Tumor Suppressors

Hypermethylation-driven silencing removes cellular safeguards against uncontrolled division, defective DNA repair, and evasion of programmed cell death, functioning as an alternative to mutational inactivation and often converging on the same critical pathways.

Genomic Instability

Hypomethylation-associated loosening of repetitive and pericentromeric chromatin increases the frequency of chromosome mis-segregation, structural rearrangements, and retrotransposon mobilization, compounding the mutational burden of the tumor over time.

Field Effects and Early Detection

Because promoter hypermethylation often occurs early and can be detected in histologically normal tissue surrounding a tumor, methylation alterations serve as sensitive biomarkers for early cancer detection and risk stratification, including in minimally invasive assays performed on blood or other bodily fluids.

Therapeutic Targeting

Demethylating Agents

Inhibitors of DNA methyltransferase activity are used clinically to reverse aberrant promoter hypermethylation, reactivating silenced tumor suppressor genes and restoring normal differentiation programs, particularly in hematologic malignancies where methylation alterations play a prominent role.

Combination Approaches

Because DNA methylation alterations frequently act together with histone modification changes to silence genes, demethylating agents are increasingly combined with agents targeting histone-modifying enzymes to achieve more durable reactivation of silenced genetic programs.